CINECA IRIS Institutional Research Information System

BONORA, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16724
EU - Europa 11413
AS - Asia 4289
SA - Sud America 246
AF - Africa 197
OC - Oceania 66
Continente sconosciuto - Info sul continente non disponibili 25
Totale 32960
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16458
CN - Cina 2865
IT - Italia 1874
DK - Danimarca 1817
IE - Irlanda 1270
DE - Germania 1130
SE - Svezia 1057
FR - Francia 962
UA - Ucraina 719
FI - Finlandia 666
GB - Regno Unito 555
KR - Corea 511
AT - Austria 353
PL - Polonia 298
VN - Vietnam 251
CA - Canada 189
IN - India 165
ES - Italia 156
NL - Olanda 128
BE - Belgio 113
JP - Giappone 104
BR - Brasile 103
RO - Romania 80
ZA - Sudafrica 71
TW - Taiwan 68
ID - Indonesia 62
MX - Messico 60
AU - Australia 59
TH - Thailandia 57
RU - Federazione Russa 55
CH - Svizzera 50
AR - Argentina 45
TR - Turchia 42
CO - Colombia 33
PT - Portogallo 26
HK - Hong Kong 25
PE - Perù 25
CL - Cile 24
GR - Grecia 23
PK - Pakistan 23
EU - Europa 22
IL - Israele 20
UZ - Uzbekistan 19
KE - Kenya 16
IR - Iran 15
SN - Senegal 14
UG - Uganda 12
BG - Bulgaria 11
ET - Etiopia 11
EG - Egitto 10
HR - Croazia 10
PH - Filippine 10
SG - Singapore 10
CZ - Repubblica Ceca 9
NG - Nigeria 9
NO - Norvegia 9
EC - Ecuador 7
MU - Mauritius 7
MY - Malesia 7
NZ - Nuova Zelanda 7
HU - Ungheria 6
SA - Arabia Saudita 6
SD - Sudan 6
SK - Slovacchia (Repubblica Slovacca) 6
TN - Tunisia 6
LV - Lettonia 5
RS - Serbia 5
TZ - Tanzania 5
AE - Emirati Arabi Uniti 4
CR - Costa Rica 4
CU - Cuba 4
JO - Giordania 4
MW - Malawi 4
MZ - Mozambico 4
BO - Bolivia 3
BY - Bielorussia 3
CD - Congo 3
CM - Camerun 3
EE - Estonia 3
GT - Guatemala 3
KZ - Kazakistan 3
LU - Lussemburgo 3
MD - Moldavia 3
PA - Panama 3
VE - Venezuela 3
AP - ???statistics.table.value.countryCode.AP??? 2
BJ - Benin 2
BT - Bhutan 2
DZ - Algeria 2
GA - Gabon 2
GH - Ghana 2
IQ - Iraq 2
LI - Liechtenstein 2
LK - Sri Lanka 2
LT - Lituania 2
MO - Macao, regione amministrativa speciale della Cina 2
NA - Namibia 2
NP - Nepal 2
QA - Qatar 2
ZW - Zimbabwe 2
Totale 32939
Salva come PNG Salva come JPEG
Città #
Ann Arbor 3772
Beijing 2189
Chandler 1952
Dublin 1266
Houston 1188
Fairfield 881
Villeurbanne 622
Wilmington 601
Torino 554
Jacksonville 529
Dearborn 479
Medford 467
Princeton 441
Woodbridge 431
Redwood City 384
Ashburn 345
Nyköping 314
Vienna 298
Seattle 293
Warsaw 284
Cambridge 268
Pisa 183
Milan 170
Boston 131
Fremont 128
Dong Ket 116
Boardman 111
Brussels 89
Toronto 76
Verona 75
Guangzhou 68
Turin 65
San Diego 64
Nanjing 57
Shanghai 57
Hangzhou 53
Norwalk 52
Taipei 50
Hefei 49
Kunming 48
Paris 45
Rome 42
Munich 39
Nürnberg 38
Chicago 35
Falls Church 35
Ottawa 31
Jinan 30
New York 30
Phoenix 30
Seoul 28
Mountain View 27
Buenos Aires 26
Chengdu 26
London 25
São Paulo 25
Jakarta 24
Silver Spring 24
Lachine 23
Santiago 22
Buffalo 21
Dallas 21
Hebei 21
Tokyo 21
Lima 20
Changsha 19
Upper Marlboro 19
Des Moines 18
Hanoi 18
Los Angeles 18
Tariceni 18
Toulouse 18
Amsterdam 17
Zhengzhou 17
Duncan 16
Barcelona 15
Leawood 15
Nanchang 15
Omaha 15
Piemonte 15
Atlanta 14
Baltimore 14
Bengaluru 14
Edinburgh 14
Kharkiv 14
Madrid 14
Shenyang 14
Wuhan 14
Minneapolis 13
Bogotá 12
Cape Town 12
Helsinki 12
Istanbul 12
Mexico 12
Rotterdam 12
San Mateo 12
Bologna 11
Chongqing 11
Göteborg 11
Montreal 11
Totale 20415
Salva come PNG Salva come JPEG
Nome #
Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? 664
Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system. 646
Cytomegalovirus central nervous system compartmentalization in a patient presenting with AIDS 543
Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era 425
The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment 352
Antiretroviral therapy in geriatric HIV patients: The GEPPO cohort study 350
Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients 330
Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-positive Patients are Associated with Compartmental Viral Control. 324
High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: A meta-analysis 308
High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. 290
Heart failure in patients with human immunodeficiency virus: a review of the literature. 277
Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting 273
Prevalence and predictors of long corrected QT interval in HIV-positive patients: a multicenter study 271
A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs 271
Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. 268
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. 264
HIV-1 Very Low Level Viremia is Associated with Virological Failure in HAART-treated Patients 259
Raltegravir penetration in seminal plasma of healthy volunteers. 241
Tenofovir clearance is reduced in hiv-positive patients with subclinical tubular impairment 240
Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. 237
Are intracellular drug concentrations underestimated? The role of medium corpuscular volume (MCV) for a correct determination 222
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T influence plasma concentrations of Efavirenz (EFV). 222
Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. 221
A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease 210
CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose 209
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study) 206
Presence of EBV DNA in Cerebrospinal Fluid is Associated with Greater HIV RNA and Inflammation 202
Extra Corporeal Membrane Oxygenation (ECMO) in three HIV-positive patients with acute respiratory distress syndrome 192
Pharmacogenetics of Antiretrovirals' Penetrations into Cerebrospinal Fluid 192
Descrittiva della farmacocinetica (PK) e della farmacogenetica (PG) dell'Efavirenz in una coorte di popolazione italiana 190
SLC28A2 65C>T predict Sustained Virological Response in patients with hepatitis C treated with interferon and ribavirin, considering all HCV genotype and genotype 1/4. 189
Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid 185
Prevalence and predictors of blood-brain barrier damage in the HAART era. 184
Acute HIV infection: Improved algorithms for HIV testing. 183
Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. 173
Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens 170
Could ritonavir intracellular concentrations have a role as active drugs when used as a booster PIs? 170
Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia 167
West African Immigrants and New Patterns of Malaria Imported to North Eastern Italy. 166
SLC29A1 −706G>C predict haemoglobin decrease in patients with hepatitis C treated with interferon and ribavirin 166
An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients 165
Cardiovascular disease in HIV patients: from bench to bedside and backwards 163
Effect of Darunavir (DRV) genotypic inhibitory quotient (gIQ) on the virological response to DRV-containing salvage regimens at 24 weeks 161
Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines 157
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV 156
Failure of prophylaxis against PCP in patients with HIV infection. 155
Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting 155
A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance 153
TENOFOVIR AND EMTRICITABINE CSF-TO-PLASMA RATIOS CORRELATE TO THE EXTENT OF BLOOD BRAIN-BARRIER DAMAGE 152
INTRACELLULAR ACCUMULATION OF RITONAVIR ASSOCIATED WITH DIFFERENT BOOSTED PIS 150
Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. 149
Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting 148
Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. 147
Etravirine Plasma Exposure is Associated with Virological Efficacy in Treatment-experienced HIV-positive Patients. 147
Role of therapeutic drug monitoring in a patient with human immunodeficiency virus infection and end-stage liver disease undergoing orthotopic liver transplantation 147
Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. 146
Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors. 146
An improved HPLC fluorimetric method for the determination of enfuvirtide plasma levels in HIV-infected patients 145
What do we know about tailoring treatment with tenofovir? 144
A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients. 144
Clinical pharmacology of complex regiment of antiretroviral therapy including Etravirine, Maraviroc and Raltégravir. 143
Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients 142
A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. 142
Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-sectional Study in HIV-positive Patients with Normal Renal Function. 141
Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage. 141
Determinants of Tenofovir Plasma Trough Concentrations: a Cross-sectional Analysis in the Clinical Setting 140
Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients 140
A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. 140
Undetectable Ritonavir Plasma Concentrations in Different Boosted PI-based Regimens as a Marker of Non-Adherence: analysis of a large TDM Registry 139
Single-nucleotide polymorphism PXR 7635G>A influences plasma concentrations of Efavirenz in CYP2B6 516G>T carriers 139
Pharmacokinetic Determinants of Immunovirological Response in HIV Very Late Presenters 137
Viral rebound after switch to Maraviroc-Raltegravir dual therapy 137
MONITORING OF VIROLOGICAL AND PHARMACOLOGICAL CEREBROSPINAL FLUID PARAMETERS IN HAART-TREATED HIV-POSITIVE PATIENTS IN THE CLINICAL SETTING 136
Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject 135
HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients 135
Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients 134
Continuous intravenous infusion of enfuvirtide in an out-clinic patient with a multi resistent HIV strain and severe injection-site reactions 134
Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. 134
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load 133
Efficacy, Safety and Pharmacokinetics of Atazanavir (200 mg twice-daily) plus Raltegravir (400 mg twice-daily) Dual Regimen in the Clinical Setting 133
Pharmacokinetics of Raltegravir, Etravirine and Maraviroc regimen in the clinical setting 133
SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV infected patients 132
High Interpatient Variability of Raltegravir Cerebrospinal Fluid Concentrations in HIV-positive Patients: a Pharmacogenetic Analysis 131
Intracellular accumulation of the new integrase inhibitors elvitegravir and dolutegravir in HIV patients 131
Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. 131
Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study. 129
Steady-state Raltegravir Penetration in Seminal Plasma of Healthy Volunteers 128
Pharmacokinetics of the Dual NRTI- and Protease Inhibitor-sparing Regimen Raltegravir plus Nevirapine in HIV-1+ Patients 128
Pharmacokinetics (PK) of the co-administration of raltegravir (RAL) and amlodipine (AML) to male and female healthy volunteers 127
Detectable cerebrospinal fluid JCV DNA in late-presenting HIV-positive patients: beyond progressive multifocal leukoencephalopathy? 127
GREATER IMMUNOLOGICAL RECOVERY ASSOCIATED WITH ADDITIONAL ENFUVIRTIDE IN THE TREATMENT OF NAIVE HIV-INFECTED PATIENTS AT VERY ADVANCED DISEASE STAGES: 24-WEEK RESULTS OF A RANDOMIZED, CONTROLLED, PILOT STUDY 127
Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics 126
Pharmacokinetics (PKS) of rifabutin (RIF) coadministered with lopinavir/ritonavir (LPV/r) in HIV patients affected by tuberculosis (TB) 125
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014 124
Intracellular Pharmacokinetics of Boosted and Unboosted Atazanavir in HIV Infected Patients 123
Population pharmacokinetics of unboosted atazanavir and influence of the pregnane -x- receptor PXR 63396C > T 123
Is peritoneal fluid a sanctuary site for HIV? 122
Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers. 122
Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs 122
Is Maraviroc a substrate for SLCO1B1? 121
Totale 18969
Salva come PNG Salva come JPEG
Categoria #
all - tutte 58271
article - articoli 0
book - libri 0
conference - conferenze 12409
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 70680
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201898 0000 00 00 00098
2018/20192918 13170179107 137272 175398 198267657327
2019/20206910 218214267607 7871419 649358 411575658747
2020/20214466 615197249246 404359 323159 447371316780
2021/20226295 540453545604 429439 562512 352256714889
2022/20236097 631368123579 6511584 532466 6931273430
Totale 34617